Cor Vasa 2021, 63(5):572-578 | DOI: 10.33678/cor.2021.049

Association between SYNTAX score-II and no-reflow in patients with acute anterior ST-segment elevation myocardial infarction

Hazar Harbalioğlua, Ömer Gençb, Alaa Quisic, Abdullah Yildirimd, İbrahim Halil Kurtd
a Department of Cardiology, Duzce Ataturk State Hospital, Duzce/Turkey
b Department of Cardiology, Ağri Training and Research Hospital, Ağri/Turkey
c Department of Cardiology, Medline Adana Hospital, Adana, Turkey
d Department of Cardiology, University of Health Sciences - Adana Health Practices and Research Center, Adana, Turkey

Background and objectives: The no-reflow phenomenon associated with cardiovascular mortality is one of the serious complications of percutaneous coronary intervention. Also, having both clinical and angiographic parameters, SYNTAX score-II (SS-II) predicts mortality in patients with acute coronary syndrome (ACS). The aim of this study is to investigate the association of the no-reflow phenomenon with SS-II.

Subjects and methods: 255 consecutive participants (210 [82.3%] male, median age; 55 [18-90] with acute anterior ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention were enrolled in the study. Patients were divided into two groups as follows: those with no-reflow and those with reflow. Demographic features, comorbidities, biochemical parameters were recorded. SYNTAX score-I (SS-I), and SS-II of the patients were calculated.

Results: No-reflow group was older. Hypertension was more frequent in the no-reflow group than that of the re-flow group (p = 0.007). Troponin levels (both on admission and peak), TIMI frame count, SS-I, and SS-II were significantly higher in patients with no-reflow. In logistic regression analysis, SS-II (odds ratio [OR]: 1.096, 95% confidence interval [CI]: 1.058-1.135; p< 0.001) was independently associated with the no-reflow phenomenon. A cut-off value of ≥ 24.85 predicted no-reflow, with 75.9% sensitivity and 59.2% specificity (AUC: 0.721 [0.637-0.805], 95% CI, p< 0.001) in ROC curve analysis.

Conclusion: In STEMI patients, particularly acute anterior MI, SS-II is independently associated with the no-reflow phenomenon, which is a fatal and frequent complication of ACS.

Keywords: Coronary artery disease, No-reflow phenomenon, Smoking, SYNTAX score-II

Received: March 22, 2021; Revised: April 6, 2021; Accepted: April 7, 2021; Published: October 20, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Harbalioğlu H, Genç Ö, Quisi A, Yildirim A, Kurt İH. Association between SYNTAX score-II and no-reflow in patients with acute anterior ST-segment elevation myocardial infarction. Cor Vasa. 2021;63(5):572-578. doi: 10.33678/cor.2021.049.
Download citation

References

  1. Townsend N, Wilson L, Bhatnagar P, et al. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J 2016;37:3232-3245. Go to original source... Go to PubMed...
  2. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patientspresenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39:119-177. Go to original source... Go to PubMed...
  3. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol 2009;54:281-292. Go to original source... Go to PubMed...
  4. Ito H, Iwakura K. Assessing the relation between coronary reflow and myocardial reflow. Am J Cardiol 1998;81:8g-12g. Go to original source... Go to PubMed...
  5. Bouleti C, Mewton N, Germain S. The no-reflow phenomenon: State of the art. Arch Cardiovasc Dis 2015;108:661-674. Go to original source... Go to PubMed...
  6. Fugit MD, Rubal BJ, Donovan DJ. Effects of intracoronary nicardipine, diltiazem and verapamil on coronary blood flow. J Invasive Cardiol 2000;12:80-85. Go to PubMed...
  7. Ito H, Okamura A, Iwakura K, et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation 1996;93:1993-1999. Go to original source... Go to PubMed...
  8. Minamisawa M, Miura T, Motoki H, et al. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with prior heart failure undergoing percutaneous coronary intervention: sub-analysis of the SHINANO registry. Heart Vessels 2017;32:399-407. Go to original source... Go to PubMed...
  9. Farooq V, van Klaveren D, Steyerberg EW, et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet 2013;381:639-650. Go to original source... Go to PubMed...
  10. Xu B, Généreux P, Yang Y, et al. Validation and comparison of the long-term prognostic capability of the SYNTAX score-II among 1,528 consecutive patients who underwent left main percutaneous coronary intervention. JACC Cardiovasc Interv 2014;7:1128-1137. Go to original source... Go to PubMed...
  11. He J, Zhao H, Yu X, et al. SYNTAX Score-II Predicts Long-Term Mortality in Patients Who Underwent Left Main Percutaneous Coronary Intervention Treated With Second-Generation Drug-Eluting Stents. Int Heart J 2017;58:344-350. Go to original source... Go to PubMed...
  12. Brener SJ, Alapati V, Chan D, et al. The SYNTAX II Score Predicts Mortality at 4 Years in Patients Undergoing Percutaneous Coronary Intervention. J Invasive Cardiol 2018;30:290-294. Go to PubMed...
  13. Fourth universal definition of myocardial infarction (2018). Rev Esp Cardiol (Engl Ed) 2019;72(1):72. Go to PubMed...
  14. Williams B, Mancia G, Spiering W, et al. [2018 ESC/ESH Guidelines for the management of arterial hypertension]. Kardiol Pol 2019;77:71-159. Go to original source... Go to PubMed...
  15. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis 2019;290:140-205.
  16. Petersmann A, Müller-Wieland D, Müller UA, et al. Definition, Classification and Diagnosis of Diabetes Mellitus. Exp Clin Endocrinol Diabetes 2019;127:S1-S7. Go to original source... Go to PubMed...
  17. Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation 1994;89:2514-2518. Go to original source... Go to PubMed...
  18. Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996;93:879-888. Go to original source... Go to PubMed...
  19. Balkissoon R. Journal Club-COPD2020 Update. Global Initiative for Chronic Obstructive Lung Disease 2020 Report and the Journal of the COPD Foundation Special Edition, Moving to a New Definition for COPD: "COPDGene(®) 2019". Chronic Obstr Pulm Dis 2019;6:64-72. Go to original source... Go to PubMed...
  20. Aboyans V, Ricco JB, Bartelink ML, et al. [2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)]. Kardiol Pol 2017;75:1065-1160. Go to original source... Go to PubMed...
  21. Şahin DY, Gür M, Elbasan Z, et al. SYNTAX score is a predictor of angiographic no-reflow in patients with ST-elevation myocardial infarction treated with a primary percutaneous coronary intervention. Coron Artery Dis 2013;24:148-153. Go to original source... Go to PubMed...
  22. Alidoosti M, Lotfi R, Lotfi-Tokaldany M, et al. Correlates of the "No-Reflow" or "Slow-Flow" Phenomenon in Patients Undergoing Primary Percutaneous Coronary Intervention. J Tehran Heart Cent 2018;13:108-114. Go to original source...
  23. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 2002;105:656-662. Go to original source... Go to PubMed...
  24. Harrison RW, Aggarwal A, Ou FS, et al. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. Am J Cardiol 2013;111:178-184. Go to original source... Go to PubMed...
  25. Jaffe R, Charron T, Puley G, et al. Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation 2008;117:3152-3156. Go to original source... Go to PubMed...
  26. Furuichi K, Wada T, Iwata Y, et al: Interleukin-1-dependent sequential chemokine expression and inflammatory cell infiltration in ischemia-reperfusion injury. Crit Care Med 2006;34:2447-2455. Go to original source... Go to PubMed...
  27. Skyschally A, Leineweber K, Gres P, et al. Coronary microembolization. Basic Res Cardiol 2006;101:373-382. Go to original source... Go to PubMed...
  28. Carden DL, Granger DN. Pathophysiology of ischaemia-reperfusion injury. J Pathol 2000;190:255-266. Go to original source...
  29. Ndrepepa G, Tiroch K, Fusaro M, et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol 2010;55:2383-2389. Go to original source... Go to PubMed...
  30. Farooq V, Serruys PW, Bourantas C, et al. Incidence and multivariable correlates of long-term mortality in patients treated with surgical or percutaneous revascularization in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial. Eur Heart J 2012;33:3105-3113. Go to original source... Go to PubMed...
  31. Aşkin L, Aktürk E. Association between SYNTAX II score and electrocardiographic evidence of no-reflow in patients withST-segment elevation myocardial infarction. Turk Kardiyol Dern Ars 2018;46:455-463. Go to original source... Go to PubMed...
  32. Yesin M, Çağdaş M, Kalçik M, et al. Comparison of syntax score and syntax score II to predict "no reflow phenomenon" in patients with ST-segment elevation myocardial infarction. Int J Cardiovasc Imaging 2017;33:1883-1889. Go to original source... Go to PubMed...
  33. Magro M, Nauta ST, Simsek C, et al. Usefulness of the SYNTAX score to predict "no reflow" in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Am J Cardiol 2012;109:601-606. Go to original source... Go to PubMed...
  34. Wagdy S, Sobhy M, Loutfi M. Neutrophil/Lymphocyte Ratio as a Predictor of In-Hospital Major Adverse Cardiac Events, New-Onset Atrial Fibrillation, and No-Reflow Phenomenon in Patients with ST Elevation Myocardial Infarction. Clin Med Insights Cardiol 2016;10:19-22. Go to original source... Go to PubMed...
  35. Liang T, Liu M, Wu C, et al. Risk Factors for No-Reflow Phenomenon after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome. Rev Invest Clin 2017;69:139-145. Go to original source... Go to PubMed...
  36. Arbel Y, Rind E, Banai S, et al. Prevalence and predictors of slow flow in angiographically normal coronary arteries. Clin Hemorheol Microcirc 2012;52:5-14. Go to original source... Go to PubMed...
  37. Hong YJ, Jeong MH, Choi YH, et al. Impact of plaque components on no-reflow phenomenon after stent deployment in patients with acute coronary syndrome: a virtual histology-intravascular ultrasound analysis. Eur Heart J 2011;32:2059-2066. Go to original source... Go to PubMed...
  38. Shemirani H, Tafti FD, Amirpour A. Comparison of no-reflow phenomenon after percutaneous coronary intervention for acute myocardial infarction between smokers and nonsmokers. J Res Med Sci 2014;19:1068-1073.
  39. Albertal M, Cura F, Escudero AG, et al. Mechanism involved in the paradoxical effects of active smoking following primary angioplasty: a subanalysis of the protection of distal embolization in high-risk patients with acute myocardial infarction trial. J Cardiovasc Med (Hagerstown) 2008;9:810-812. Go to original source... Go to PubMed...
  40. Ndrepepa G, Tiroch K, Keta D, et al. Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction. Circ Cardiovasc Interv 2010;3:27-33. Go to original source... Go to PubMed...
  41. Grines CL, Topol EJ, O'Neill WW, et al. Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction. Circulation 1995;91:298-303. Go to original source... Go to PubMed...
  42. Andrikopoulos GK, Richter DJ, Dilaveris PE, et al. In-hospital mortality of habitual cigarette smokers after acute myocardial infarction; the "smoker's paradox" in a countrywide study. Eur Heart J 2001;22:776-784. Go to original source... Go to PubMed...

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.





Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.